Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241345 | 0.83 | LMNA (0.59) | KMT2APOLBKDM4ELMNAMAPT | |
| SCHEMBL237311 | 0.81 | KMT2A (0.58) | KMT2APOLBNAMPTHRH3MEN1 | |
| SCHEMBL14558058 | 0.74 | NAMPT (0.56) | KMT2APOLBNAMPTLMNAHRH3 | |
| SCHEMBL237614 | 0.73 | NAMPT (0.52) | KMT2APOLBNAMPTLMNAMAPT | |
| SCHEMBL14403033 | 0.72 | NAMPT (0.50) | KMT2APOLBNAMPTLMNAHRH3 | |
| SCHEMBL14569674 | 0.70 | NAMPT (0.57) | KMT2APOLBNAMPTLMNAMEN1 | |
| SCHEMBL14402772 | 0.69 | NAMPT (0.50) | KMT2APOLBNAMPTLMNAMAPT | |
| SCHEMBL13838917 | 0.68 | HRH3 (0.39) | KMT2AHRH3 | |
| SCHEMBL3818108 | 0.68 | SMYD3 (0.42) | LMNAHRH3 | |
| SCHEMBL14610952 | 0.67 | SRD5A1 (0.51) | KMT2APOLBNAMPTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | claimed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | claimed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | KMT2A 3823/4885POLB 912/4885NAMPT 1725/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | KMT2A 3848/4885POLB 859/4885NAMPT 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.